44.1 F
Elizabeth City
Wednesday, March 3, 2021

Practice-Changing Trial in Metastatic Papillary RCC

Must read

(MedPage Today) — Cabozantinib (Cabometyx) came out on top as upfront therapy in metastatic papillary renal cell carcinoma (RCC) in a randomized phase II study.
Treatment with the multikinase inhibitor yielded a median progression-free survival…
Read More

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article